Cargando…
Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge
BACKGROUND: The introduction of the immunomodulatory drug lenalidomide has revolutionized the treatment of patients with myelodysplastic syndromes (MDS) and deletion of the long arm of chromosome 5. Treatment with lenalidomide results in transfusion independence in the majority of patients, but some...
Autores principales: | Pisani, Francesco, Orlandi, Giulia, Merola, Roberta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036206/ https://www.ncbi.nlm.nih.gov/pubmed/24926257 http://dx.doi.org/10.1159/000362643 |
Ejemplares similares
-
Resolution of Cystic Enhancement to Add-On Tumor Treating Electric Fields for Recurrent Glioblastoma after Incomplete Response to Bevacizumab
por: Elzinga, Grace, et al.
Publicado: (2014) -
Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer
por: Shakir, Abdur R.
Publicado: (2014) -
PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report
por: Gasent Blesa, Joan Manel, et al.
Publicado: (2012) -
A Case of Metastatic Gastric Neuroendocrine Tumor: Therapeutic Considerations
por: Kim, Shin Young, et al.
Publicado: (2014) -
Cholecystocutaneous Fistula after Percutaneous Gallbladder Drainage
por: Pripotnev, Stahs, et al.
Publicado: (2014)